Prudential PLC Purchases 26,880 Shares of Qiagen N.V. $QGEN

Key Points

• Prudential PLC increased its stake in QIAGEN N.V. by 132.5%, acquiring a total of 47,166 shares, valued at approximately $1.86 million at the quarter's end.
• Several institutional investors have also increased their holdings in QIAGEN, with 70% of the company's stock owned by institutions and hedge funds.
• Wall Street analysts have mixed ratings on QIAGEN, with a consensus target price of $49.69, as analysts expect the company to generate earnings of $2.26 per share this year.

Prudential PLC lifted its stake in shares of Qiagen N.V. (NYSE:QGEN - Free Report) by 132.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 47,166 shares of the company's stock after acquiring an additional 26,880 shares during the period. Prudential PLC's holdings in Qiagen were worth $1,862,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. ANTIPODES PARTNERS Ltd acquired a new stake in Qiagen in the 1st quarter valued at $94,000. Tower Research Capital LLC TRC boosted its holdings in shares of Qiagen by 770.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,490 shares of the company's stock valued at $111,000 after buying an additional 2,204 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of Qiagen by 93.9% in the first quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock valued at $118,000 after buying an additional 1,425 shares in the last quarter. Federated Hermes Inc. bought a new stake in Qiagen during the first quarter worth $150,000. Finally, Wealth Enhancement Advisory Services LLC acquired a new stake in Qiagen in the fourth quarter valued at $202,000. Institutional investors own 70.00% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Cowen reaffirmed a "hold" rating on shares of Qiagen in a report on Thursday, August 7th. Wall Street Zen downgraded Qiagen from a "strong-buy" rating to a "buy" rating in a report on Monday, August 11th. UBS Group lifted their price objective on shares of Qiagen from $48.00 to $50.00 and gave the stock a "neutral" rating in a research note on Thursday, August 7th. Barclays started coverage on Qiagen in a report on Tuesday, June 24th. They issued an "overweight" rating and a $55.00 price objective for the company. Finally, Bank of America raised their price target on shares of Qiagen from $50.00 to $53.00 and gave the company a "buy" rating in a research note on Thursday, June 26th. Three research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company's stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $49.69.

Qiagen Stock Up 1.0%

Shares of Qiagen stock traded up $0.4850 during trading hours on Tuesday, reaching $49.1350. The company's stock had a trading volume of 446,512 shares, compared to its average volume of 1,374,522. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.35 and a current ratio of 1.61. The stock's fifty day simple moving average is $48.42 and its two-hundred day simple moving average is $43.74. The company has a market capitalization of $10.92 billion, a P/E ratio of 29.04, a P/E/G ratio of 2.59 and a beta of 0.64. Qiagen N.V. has a one year low of $37.63 and a one year high of $51.88.

Qiagen (NYSE:QGEN - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $0.60 earnings per share for the quarter, meeting the consensus estimate of $0.60. Qiagen had a return on equity of 14.77% and a net margin of 18.30%.The business had revenue of $533.54 million for the quarter, compared to analysts' expectations of $523.97 million. During the same period last year, the business earned $0.55 EPS. The business's revenue was up 7.7% on a year-over-year basis. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. On average, research analysts forecast that Qiagen N.V. will post 2.26 earnings per share for the current year.

Qiagen Dividend Announcement

The firm also recently disclosed a dividend, which was paid on Thursday, July 10th. Stockholders of record on Thursday, July 3rd were issued a dividend of $0.25 per share. The ex-dividend date of this dividend was Wednesday, July 2nd. This represents a dividend yield of 52.0%. Qiagen's payout ratio is presently 14.79%.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.